Predict your next investment

Corporation
HEALTHCARE | Biotechnology
sperotherapeutics.com

See what CB Insights has to offer

Stage

Corporate Minority - P2P | IPO

Total Raised

$116.86M

Market Cap

0.44B

Stock Price

13.56

About Spero Therapeutics

Spero Therapeutics is a global multi-asset clinical-stage biopharmaceutical company dedicated to developing a pipeline of antibacterials focused on unmet needs of patients with drug-resistant bacterial infections. Spero is advancing two lead programs in parallel, SPR741 and SPR994. SPR741, also called Potentiator, is a platform approach to combination therapy to treat serious and life-threatening multidrug-resistant Gram-negative infections, such as Enterobacteriaceae and Acinetobacter baumannii, including carbapenem-resistant strains. SPR741 increases the spectrum and potency of more than two dozen classes of Gram-positive antibiotics to include activity against multidrug-resistant Gram-negative infections when used in combination. SPR994 is an oral agent that has demonstrated potent in-vitro activity against a wide variety of Gram-negative bacteria, including extended spectrum beta lactamases (ESBLs), and Gram-positive bacteria. Spero Therapeutics also has a robust preclinical pipeline including SPR720, which is a preclinical oral therapeutic candidate for mycobacteria infections including nontuberculous mycobacteria (NTM) lung disease, a rare and often chronic fatal infection. In addition, Spero Therapeutics has a variety of other discovery stage antimicrobials focused on drug resistant infections.

Spero Therapeutics Headquarter Location

675 Massachusetts Avenue 14th Floor

Cambridge, Massachusetts, 02139,

United States

857-242-1600

Latest Spero Therapeutics News

Spero Therapeutics To Present At Upcoming Investor Conferences

Nov 17, 2021

Spero Therapeutics To Present At Upcoming Investor Conferences CAMBRIDGE, Mass., Nov. CAMBRIDGE, Mass., Nov. 17, 2021 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a multi-asset clinical-stage biopharmaceutical company focused on identifying, developing and commercializing treatments in high unmet need areas involving multi-drug resistant bacterial infections and rare diseases, today announced that Ankit Mahadevia, M.D., President and Chief Executive Officer of Spero Therapeutics, will present and be available for one-on-one meetings at the Piper Sandler 33 rd Annual Virtual Healthcare Conference and the 4 th Annual Evercore ISI HealthCONx Conference, which are taking place virtually, November 29, 2021 through December 2, 2021 and November 30, 2021 through December 2, 2021, respectively. Details for the presentations are as follows. Piper Sandler 33 rd Annual Virtual Healthcare Conference Presentation Format: On-demand corporate presentationPresentation Date & Time: Available beginning at 2:00 PM ET on November 24, 2021 4 th Annual Evercore ISI HealthCONx Conference Presentation Format: Fireside chatPresentation Date & Time: December 1, 2021, at 3:05 PM ET Webcasts of the presentations may be accessed through Spero Therapeutics' website ( www.sperotherapeutics.com ) on the "Events and Presentations" page under the "Investors and Media" tab. Replays of the presentations will be available on the website following the conclusion of the event. About Spero  TherapeuticsSpero Therapeutics, Inc. is a multi-asset, clinical-stage biopharmaceutical company focused on identifying, developing and commercializing novel treatments for multi-drug-resistant (MDR) bacterial infections and rare diseases. Spero's lead product candidate, tebipenem HBr (tebipenem pivoxil hydrobromide; formerly SPR994), is being developed as the first oral carbapenem antibiotic for use in cUTI, including pyelonephritis. In October 2021, Spero filed an NDA for tebipenem HBr tablets, which included positive top-line results from its Phase 3 ADAPT-PO clinical trial of tebipenem HBr in cUTI and AP. Tebipenem HBr is an investigational drug in the United States and is currently not approved for the treatment of complicated urinary tract infection, including pyelonephritis. Spero is also developing SPR720 as a novel oral therapy product candidate for the treatment of a rare, orphan pulmonary disease caused by non-tuberculous mycobacterial infections. Spero also has an IV-administered next generation polymyxin product candidate, SPR206, developed from its potentiator platform, which is being developed to treat MDR Gram-negative infections in the hospital setting. For more information, visit  https://sperotherapeutics.com . Investor Relations Contact: Ted JenkinsVice President, Head of Investor Relations Tjenkins@sperotherapeutics.com (617) 798-4039

Predict your next investment

The CB Insights tech market intelligence platform analyzes millions of data points on venture capital, startups, patents , partnerships and news mentions to help you see tomorrow's opportunities, today.

Expert Collections containing Spero Therapeutics

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

Spero Therapeutics is included in 1 Expert Collection, including Biopharmaceuticals.

B

Biopharmaceuticals

14,140 items

Companies involved in the research, development, and commercialization of chemically- or biologically-derived therapeutic & theranostic drugs. Excludes vitamins/supplements, CROs/clinical trial services.

Spero Therapeutics Patents

Spero Therapeutics has filed 8 patents.

The 3 most popular patent topics include:

  • Animal fungal diseases
  • Calcium channel blockers
  • Dosage forms
patents chart

Application Date

Grant Date

Title

Related Topics

Status

2/6/2018

1/12/2021

Metal halides, Calcium channel blockers, Orthorhombic minerals, Sedatives, Carboxamides

Grant

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

00/00/0000

00/00/0000

Subscribe to see more

Subscribe to see more

Subscribe to see more

Application Date

2/6/2018

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Grant Date

1/12/2021

00/00/0000

00/00/0000

00/00/0000

00/00/0000

Title

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Related Topics

Metal halides, Calcium channel blockers, Orthorhombic minerals, Sedatives, Carboxamides

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Status

Grant

Subscribe to see more

Subscribe to see more

Subscribe to see more

Subscribe to see more

Spero Therapeutics Web Traffic

Rank
Page Views per User (PVPU)
Page Views per Million (PVPM)
Reach per Million (RPM)
CBI Logo

Spero Therapeutics Rank

CB Insights uses Cookies

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.